当前位置: 首页 >> 检索结果
1121. CARD9 in neutrophils protects from colitis and controls mitochondrial metabolism and cell survival.
作者: Camille Danne.;Chloé Michaudel.;Jurate Skerniskyte.;Julien Planchais.;Aurélie Magniez.;Allison Agus.;Marie-Laure Michel.;Bruno Lamas.;Gregory Da Costa.;Madeleine Spatz.;Cyriane Oeuvray.;Chloé Galbert.;Maxime Poirier.;Yazhou Wang.;Alexia Lapière.;Nathalie Rolhion.;Tatiana Ledent.;Cédric Pionneau.;Solenne Chardonnet.;Floriant Bellvert.;Edern Cahoreau.;Amandine Rocher.;Rafael Rose Arguello.;Carole Peyssonnaux.;Sabine Louis.;Mathias L Richard.;Philippe Langella.;Jamel El-Benna.;Benoit Marteyn.;Harry Sokol.
来源: Gut. 2023年72卷6期1081-1092页
Inflammatory bowel disease (IBD) results from a combination of genetic predisposition, dysbiosis of the gut microbiota and environmental factors, leading to alterations in the gastrointestinal immune response and chronic inflammation. Caspase recruitment domain 9 (Card9), one of the IBD susceptibility genes, has been shown to protect against intestinal inflammation and fungal infection. However, the cell types and mechanisms involved in the CARD9 protective role against inflammation remain unknown.
1122. Alterations to the duodenal microbiota are linked to gastric emptying and symptoms in functional dyspepsia.
作者: Erin R Shanahan.;Seungha Kang.;Heidi Staudacher.;Ayesha Shah.;Anh Do.;Grace Burns.;Veronique S Chachay.;Natasha A Koloski.;Simon Keely.;Marjorie M Walker.;Nicholas J Talley.;Mark Morrison.;Gerald J Holtmann.
来源: Gut. 2023年72卷5期929-938页
Functional dyspepsia (FD) is a complex disorder, with debilitating epigastric symptoms. Evidence suggests alterations in gastrointestinal (GI) motility, visceral hypersensitivity, permeability and low-level immune activation in the duodenum may play a role. However, we still have a relatively poor understanding of how these factors interact to precipitate the onset of FD symptoms which are frequently meal related. The duodenal microbiota, in combination with specific dietary substrates, may be important mediators in disease pathophysiology; however, these interlinked factors have not been thoroughly investigated in FD.
1123. Genetic analyses of treatment response in primary care IBS, a pilot study.
作者: Lukas Michaja Balsiger.;Karen Van den Houte.;Tenghao Zheng.;Joran Toth.;Linde Besard.;Andre Franke.;Mauro D'Amato.;Jan Tack.;Florencia Carbone.
来源: Gut. 2023年72卷9期1803-1804页 1124. SARS-CoV-2 Omicron variant infection was associated with higher morbidity in patients with cirrhosis.
作者: Anand V Kulkarni.;Chandan S Metage.;Baqar Ali Gora.;Sowmya Tirumalle.;Kalyan Rakam.;Anveshi Satyavadi.;Mithun Sharma.;Sameer Shaik.;Deepika Gujjarlapudi.;Padaki Nagaraja Rao.;D Nageshwar Reddy.
来源: Gut. 2023年72卷10期1995-1996页 1127. Mass cytometry-based peripheral blood analysis as a novel tool for early detection of solid tumours: a multicentre study.
作者: Qi Zhang.;Mao Ye.;Cheng Lin.;Manyi Hu.;Yangyang Wang.;Yu Lou.;Quanming Kong.;Jungang Zhang.;Junjian Li.;Yuhua Zhang.;Tianxing Yang.;Xu Sun.;Weiyun Yao.;Yongfei Hua.;Haifeng Huang.;Minghui Xu.;Xiaoguang Wang.;Xin Yu.;Weifeng Tao.;Runtian Liu.;Yuming Gao.;Tian Wang.;Jianing Wang.;Xiaobao Wei.;Jiangchao Wu.;Zhengping Yu.;Chengwu Zhang.;Chaohui Yu.;Xueli Bai.;Tingbo Liang.
来源: Gut. 2023年72卷5期996-1006页
Early detection of a tumour remains an unmet medical need, and approaches with high sensitivity and specificity are urgently required. Mass cytometry time-of-flight (CyTOF) is a powerful technique to profile immune cells and could be applied to tumour detection. We attempted to establish diagnostic models for hepatocellular carcinoma (HCC) and pancreatic ductal adenocarcinoma (PDAC).
1128. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma.
作者: Mónica P de Andrés.;Richard J Jackson.;Irene Felipe.;Sladjana Zagorac.;Christian Pilarsky.;Anna Melissa Schlitter.;Jaime Martinez de Villareal.;Gun Ho Jang.;Eithne Costello.;Steve Gallinger.;Paula Ghaneh.;William Greenhalf.;Thomas Knösel.;Daniel H Palmer.;Petra Ruemmele.;Wilko Weichert.;Markus Buechler.;Thilo Hackert.;John P Neoptolemos.;Faiyaz Notta.;Núria Malats.;Paola Martinelli.;Francisco X Real.
来源: Gut. 2023年72卷3期535-548页
GATA6 is a key regulator of the classical phenotype in pancreatic ductal adenocarcinoma (PDAC). Low GATA6 expression associates with poor patient outcome. GATA4 is the second most expressed GATA factor in the pancreas. We assessed whether, and how, GATA4 contributes to PDAC phenotype and analysed the association of expression with outcome and response to chemotherapy.
1129. Biopsy and blood-based molecular biomarker of inflammation in IBD.
作者: Carmen Argmann.;Ruixue Hou.;Ryan C Ungaro.;Haritz Irizar.;Zainab Al-Taie.;Ruiqi Huang.;Roman Kosoy.;Swati Venkat.;Won-Min Song.;Antonio F Di'Narzo.;Bojan Losic.;Ke Hao.;Lauren Peters.;Phillip H Comella.;Gabrielle Wei.;Ashish Atreja.;Milind Mahajan.;Alina Iuga.;Prerak T Desai.;Patrick Branigan.;Aleksandar Stojmirovic.;Jacqueline Perrigoue.;Carrie Brodmerkel.;Mark Curran.;Joshua R Friedman.;Amy Hart.;Esi Lamousé-Smith.;Jan Wehkamp.;Saurabh Mehandru.;Eric E Schadt.;Bruce E Sands.;Marla C Dubinsky.;Jean-Frederic Colombel.;Andrew Kasarskis.;Mayte Suárez-Fariñas.
来源: Gut. 2023年72卷7期1271-1287页
IBD therapies and treatments are evolving to deeper levels of remission. Molecular measures of disease may augment current endpoints including the potential for less invasive assessments.
1131. Human gut microbiota after bariatric surgery alters intestinal morphology and glucose absorption in mice independently of obesity.
作者: Fernando F Anhê.;Soumaya Zlitni.;Song-Yang Zhang.;Béatrice So-Yun Choi.;Cassandra Y Chen.;Kevin P Foley.;Nicole G Barra.;Michael G Surette.;Laurent Biertho.;Denis Richard.;André Tchernof.;Tony K T Lam.;Andre Marette.;Jonathan Schertzer.
来源: Gut. 2023年72卷3期460-471页
Bariatric surgery is an effective treatment for type 2 diabetes (T2D) that changes gut microbial composition. We determined whether the gut microbiota in humans after restrictive or malabsorptive bariatric surgery was sufficient to lower blood glucose.
1132. Distinct blood protein profiles associated with the risk of short-term and mid/long-term clinical relapse in patients with Crohn's disease stopping infliximab: when the remission state hides different types of residual disease activity.
作者: Nicolas Pierre.;Vân Anh Huynh-Thu.;Thomas Marichal.;Matthieu Allez.;Yoram Bouhnik.;David Laharie.;Arnaud Bourreille.;Jean-Frédéric Colombel.;Marie-Alice Meuwis.;Edouard Louis.; .
来源: Gut. 2023年72卷3期443-450页
Despite being in sustained and stable remission, patients with Crohn's disease (CD) stopping anti-tumour necrosis factor α (TNFα) show a high rate of relapse (~50% within 2 years). Characterising non-invasively the biological profiles of those patients is needed to better guide the decision of anti-TNFα withdrawal.
1133. Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals.
作者: Alessandro Mantovani.;Alessandro Csermely.;Herbert Tilg.;Christopher D Byrne.;Giovanni Targher.
来源: Gut. 2023年72卷7期1433-1436页 1134. Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment.
作者: Yibo Fan.;Yuan Li.;Xiaodan Yao.;Jiangkang Jin.;Ailing Scott.;Bovey Liu.;Shan Wang.;Longfei Huo.;Ying Wang.;Ruiping Wang.;Melissa Pool Pizzi.;Lang Ma.;Shan Shao.;Matheus Sewastjanow-Silva.;Rebecca Waters.;Deyali Chatterjee.;Bin Liu.;Namita Shanbhag.;Guang Peng.;George Adrian Calin.;Pawel Karol Mazur.;Samir M Hanash.;Jo Ishizawa.;Yuki Hirata.;Osamu Nagano.;Zhenning Wang.;Linghua Wang.;Wa Xian.;Frank McKeon.;Jaffer A Ajani.;Shumei Song.
来源: Gut. 2023年72卷4期624-637页
Many cancers engage embryonic genes for rapid growth and evading the immune system. SOX9 has been upregulated in many tumours, yet the role of SOX9 in mediating immunosuppressive tumour microenvironment is unclear. Here, we aim to dissect the role of SOX9-mediated cancer stemness attributes and immunosuppressive microenvironment in advanced gastric adenocarcinoma (GAC) for novel therapeutic discoveries.
1136. Targeted intervention to achieve waste reduction in gastrointestinal endoscopy.
作者: João A Cunha Neves.;Joana Roseira.;Patrícia Queirós.;Helena Tavares Sousa.;Gianluca Pellino.;Miguel F Cunha.
来源: Gut. 2023年72卷2期306-313页
Endoscopy is healthcare's third largest generator of medical waste in hospitals. This prospective study aimed to measure a single unit's waste carbon footprint and perform a pioneer intervention towards a more sustainable endoscopy practice. The relation of regulated medical waste (RMW; material fully contaminated with blood or body fluids or containing infectious agents) versus landfill waste (non-recyclable material not fully contaminated) may play a critical role.
1138. Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections.
作者: Rani Burm.;Panagiota Maravelia.;Gustaf Ahlen.;Sandra Ciesek.;Noelia Caro Perez.;Anna Pasetto.;Stephan Urban.;Freya Van Houtte.;Lieven Verhoye.;Heiner Wedemeyer.;Magnus Johansson.;Lars Frelin.;Matti Sällberg.;Philip Meuleman.
来源: Gut. 2023年72卷6期1186-1195页
Chronic HBV/HDV infections are a major cause of liver cancer. Current treatments can only rarely eliminate HBV and HDV. Our previously developed preS1-HDAg immunotherapy could induce neutralising antibodies to HBV in vivo and raise HBV/HDV-specific T-cells. Here, we further investigate if a heterologous prime-boost strategy can circumvent T-cell tolerance and preclude HDV superinfection in vivo.
|